Every article, report, and earnings note where INCY appears.
Devonian Health Group Inc. (NYSE: DHGR) is expected to list on 2026-08-21, but the company has not disclosed a price range yet. The setup is a clinical-stage biotech story with a commercial distribution business behind it, which gives it a real revenue base but also a financing-heavy path ahead.
Latigo Biotherapeutics, Inc. (NASDAQ: LTGO) is expected to list on 2026-08-07 at a price range of $16.00 to $18.00 per share. The company is offering 16,000,000 shares, with a disclosed market cap of $331.2 million. The bull case is a differentiated non-opioid pain platform; the bear case is a clinical-stage biotech with no revenue, rising losses, and a long road to approval.
Incyte is still being traded like Jakafi is the whole story, and that framing is getting stale. Revenue grew 21% in Q1, Jakafi XR is already approved, and a September FDA catalyst gives the pipeline a much more investable shape than the stock seems to reflect.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate INCY ReportCancel anytime